Carcinoma, Transitional Cell
"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary bladder, ureters or renal pelves (especially if well differentiated), frequently papillary. Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically benign but being liable to recurrence. (Stedman, 25th ed)
Concept/Terms
Carcinoma, Transitional Cell- Carcinoma, Transitional Cell
- Carcinomas, Transitional Cell
- Cell Carcinoma, Transitional
- Cell Carcinomas, Transitional
- Transitional Cell Carcinoma
- Transitional Cell Carcinomas
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".
This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in Harvard Catalyst Profiles by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 2 | 5 |
1995 | 4 | 4 | 8 |
1996 | 9 | 0 | 9 |
1997 | 6 | 2 | 8 |
1998 | 6 | 1 | 7 |
1999 | 4 | 0 | 4 |
2000 | 6 | 2 | 8 |
2001 | 10 | 1 | 11 |
2002 | 9 | 3 | 12 |
2003 | 16 | 2 | 18 |
2004 | 10 | 0 | 10 |
2005 | 7 | 3 | 10 |
2006 | 7 | 1 | 8 |
2007 | 8 | 0 | 8 |
2008 | 13 | 0 | 13 |
2009 | 9 | 3 | 12 |
2010 | 11 | 1 | 12 |
2011 | 11 | 0 | 11 |
2012 | 10 | 0 | 10 |
2013 | 21 | 2 | 23 |
2014 | 16 | 0 | 16 |
2015 | 17 | 3 | 20 |
2016 | 19 | 3 | 22 |
2017 | 21 | 2 | 23 |
2018 | 19 | 0 | 19 |
2019 | 20 | 3 | 23 |
2020 | 18 | 2 | 20 |
2021 | 25 | 1 | 26 |
2022 | 32 | 0 | 32 |
2023 | 26 | 0 | 26 |
2024 | 3 | 0 | 3 |
Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract. Curr Treat Options Oncol. 2024 Feb; 25(2):206-219.
-
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer. J Immunother Cancer. 2024 Feb 02; 12(2).
-
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. Clin Cancer Res. 2024 Jan 05; 30(1):63-73.
-
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events. Clin Genitourin Cancer. 2024 Apr; 22(2):368-379.
-
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors. Oncologist. 2023 Dec 11; 28(12):1072-1078.
-
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab. Pathol Res Pract. 2024 Jan; 253:155008.
-
TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary? Hum Pathol. 2024 Jan; 143:42-49.
-
Highlights in metastatic urothelial cancer from the European Society for Medical Oncology Congress 2023: commentary. Clin Adv Hematol Oncol. 2023 Dec; 21 Suppl 6(12):15-17.
-
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma. World J Urol. 2023 Dec; 41(12):3585-3591.
-
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann Oncol. 2024 Jan; 35(1):91-97.